



PerkinElmer Signs Patent License Agreement With OSRAM GmbH For White LED Components

Santa Clara, CA – February 11, 2008 – Strategies in Light Conference -PerkinElmer Optoelectronics, a global technology leader in digital imaging, specialty lighting and optical detection technologies, today announced that it has entered into a license agreement with OSRAM GmbH that enables PerkinElmer to access OSRAM white light emitting diode (LED) patents for the manufacture of LED components. OSRAM is one of the leading lighting manufacturers in the world, offering its customers solutions based on semiconductor technology for lighting, sensor and visualization applications.

Under the terms of the license, PerkinElmer gains non-exclusive, royalty bearing rights to OSRAM patents for the manufacture of white LED components for use in a variety of lighting solutions. White LEDs offer an attractive alternative to existing lamp technologies such as Halogen MR16 lamps and Cold Cathode Fluorescent lamps (CCFL) due to their higher efficiencies and longer lifetimes at attractive costs.

“Securing this important license allows PerkinElmer to add white LEDs to its range of current and future LED offerings,” said Dr. Michael Kramer, Managing Director LED Solutions. “We look forward to innovating with these ‘green,’ environmentally-efficient white LED technologies in our continued efforts to provide the most advanced lighting solutions to the medical lighting industry, as well as other markets including architectural lighting, decorative and mood lighting.”

PerkinElmer plans to incorporate white LEDs into its successful ACULED[®] platform based on chip-on-board (COB) technology. This will result in an expanded LED portfolio which includes high power, high efficiency standard white LED products under the brand name ACULED[®] VHL[™] (Very High Lumen) as well as custom combinations that include white chips under the ACULED[®] DYO[™] (design-your-own) brand name.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

For further information contact:

Heather Nevers

Brodeur
617-587-2814
hnevers@brodeur.com

Francine S. Bernitz
Director of Marketing
PerkinElmer Optoelectronics
978-224-4321
781-789-3178 (mobile)
francine.bernitz@perkinelmer.com